Efficacy and Safety of Ebronucimab, a Monoclonal Antibody Against Pcsk9, in Patients With Hyperlipidemia: Result From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Zhen, Wang
Pei, Zhaohui
Chen, Jiyan
Zhang, Guogang
Li, Dongye
Xia, Yu
Li, Baiyong
Wang, Max
Ni, Xiang
Wang, Guoqin
Ge, Junbo
机构：
来源：
CIRCULATION | 2022年 / 146卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A10451
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF EBRONUCIMAB, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III CLINICAL STUDY
    Huo, Y.
    Zheng, B.
    Xia, Y.
    Wang, M.
    Li, B.
    Ni, X.
    Wang, G.
    Yu, B.
    ATHEROSCLEROSIS, 2023, 379 : S198 - S199
  • [2] Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab
    Zhang, Yanyan
    Pei, Zhaohui
    Chen, Beijian
    Qu, Yanling
    Dong, Xiaolin
    Yu, Binge
    Wang, Guoqin
    Xu, Fang
    Lu, Dongmei
    He, Zhimei
    Chen, Benchao
    Ma, Lei
    Wang, Max
    Li, Baiyong
    Xia, Michelle
    Zheng, Bo
    Huo, Yong
    PHARMACOLOGICAL RESEARCH, 2024, 207
  • [3] PCSK9 MONOCLONAL ANTIBODY RECATICIMAB IN ADULT HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (REMAIN-3): A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY
    Chen Jiyan
    Li, Liwen
    Gao, Xiaojian
    Zhou, Yujie
    Xia, Shuang
    Sheng Jianlong
    Peng, Daoquan
    Ling, Zhiyu
    Wang, Luya
    Zhong, Tingyan
    Dai, Cuilian
    Huang, Kai
    Lian, Qiufang
    Yu, Zaixin
    Wang, Ying
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1707 - 1707
  • [4] Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
    Kastelein, John J. P.
    Nissen, Steven E.
    Rader, Daniel J.
    Hovingh, G. Kees
    Wang, Ming-Dauh
    Shen, Tong
    Krueger, Kathryn A.
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1360 - 1369
  • [5] The Double-Blind Durable Effect of PCSK9 Antibody Compared with Placebo Study (DESCARTES): A 52 Week Phase 3 Double-Blind, Randomized, Placebo-Controlled Trial of Evolocumab (AMG 145) in Hyperlipidemic Patients
    Blom, D.
    Hala, T.
    Bolognese, M.
    Lillestol, M. J.
    Toth, P. D.
    Burgess, L.
    Ceska, R.
    Roth, E.
    Koren, M. J.
    Monsalvo, M. L.
    Tsirtsonis, K.
    Kim, J. B.
    Wasserman, S. M.
    Scott, R.
    Ballantyne, C. M.
    Somaratne, R.
    Stein, E. A.
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2014, 21 : S7 - S7
  • [6] A randomized double-blind placebo-controlled phase 2 study on the efficacy and safety of fasudil in patients with stable angina
    Vicari, RM
    Chaitman, B
    Keefe, D
    Smith, WB
    Chrysant, ST
    Tonkon, MJ
    Bittar, N
    Weiss, RJ
    Thadani, U
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 254A - 254A
  • [7] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis
    Guntupalli, Kalpalatha
    Dean, Nathan
    Morris, Peter E.
    Bandi, Venkata
    Margolis, Benjamin
    Rivers, Emanuel
    Levy, Mitchell
    Lodato, Robert F.
    Ismail, Preeti M.
    Reese, Amber
    Schaumberg, John P.
    Malik, Rajesh
    Dellinger, R. Phillip
    CRITICAL CARE MEDICINE, 2013, 41 (03) : 706 - 716
  • [8] Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: A double-blind, randomized, placebo-controlled study
    Santos, AF
    Keitel, E
    Bittar, AE
    Neumann, J
    Fuchs, FD
    Goldani, JC
    Fonseca, NA
    Prates, VC
    Zaffan, D
    Voegeli, C
    Kroth, L
    Steffenello, G
    Saitovitch, D
    Garcia, VD
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1194 - 1195
  • [9] TRIAL EVALUATING EVOLOCUMAB, A PCSK9 ANTIBODY, IN PATIENTS WITH HOMOZYGOUS FH (TESLA): RESULTS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Raal, F.
    Honarpour, N.
    Blom, D. J.
    Hovingh, G. K.
    Xu, F.
    Scott, R.
    Wasserman, S. M.
    Stein, E. A.
    ATHEROSCLEROSIS, 2014, 235 (02) : E12 - E12
  • [10] Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
    Liang Dai
    Linda L. D. Zhong
    Yan Cao
    Wei Chen
    Ying Cheng
    Xiu-Fang Lin
    Zhao-Xiang Bian
    Ai-Ping Lu
    Trials, 17
12345